IONS vs ZYME · rev $226.6M vs rev $76.3M
Ionis Pharmaceuticals Inc (IONS) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Ionis Pharmaceuticals Inc (IONS) is a biotechnology company listed on NASDAQ.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported IONS revenue for 2024-12-31 was $226.6M. Net income was -$104.3M. Revenue was down 30.2% from 2023-12-31 to 2024-12-31. IONS currently screens at market cap $12.28B.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
IONS currently screens at market cap $12.28B. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the IONS and ZYME stock pages for the full models.
Not investment advice.